3.49

4.12% -0.15

After Hours: 3.49

Voyager Therapeutics Inc (VYGR)

Overview News Price History Option Chain Financials Discussions Forecast

Voyager Therapeutics Inc stock is traded at $3.49, with a volume of 310.89K. It is down -4.12% in the last 24 hours and up +12.94% over the past month. Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.

Previous Close:

$3.64

Open:

$3.62

24h Volume:

310.89K

Relative Volume:

0.89

Market Cap:

$195.26M

Revenue:

$163.78M

Net Income/Loss:

$25.88M

P/E Ratio:

5.3692

EPS:

0.65

Net Cash Flow:

$-28.66M

1W Performance:

-1.13%

1M Performance:

+12.94%

6M Performance:

-47.52%

1Y Performance:

-60.39%

1-Day Range:

$3.48

$3.645

1-Week Range:

$3.4644

$3.69

52-Week Range:

$2.75

$9.55

Voyager Therapeutics Inc Stock (VYGR) Company Profile

Name

Voyager Therapeutics Inc

Sector

Healthcare (1150)

Industry

Biotechnology (676)

Phone

857-259-5340

Address

75 HAYDEN AVENUE, LEXINGTON, MA

Employee

172

Twitter

@VoyagerTx

Next Earnings Date

2025-03-11

Latest SEC Filings

VYGR's Discussions on Twitter

Compare VYGR with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
VYGR Voyager Therapeutics Inc	3.49	195.26M	163.78M	25.88M	-28.66M	0.65
VRTX Vertex Pharmaceuticals Inc	500.19	127.64B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	603.58	65.95B	14.09B	4.50B	2.96B	39.28
ARGX Argen X Se Adr	656.65	37.92B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	273.55	32.98B	2.35B	-269.70M	-75.39M	-2.09
ONC Beigene Ltd Adr	254.16	26.92B	3.81B	-644.79M	-669.77M	-6.24

Voyager Therapeutics Inc Stock (VYGR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-10-25	Initiated	Cantor Fitzgerald	Overweight
Dec-02-24	Initiated	Citigroup	Buy
Nov-29-24	Resumed	Wedbush	Outperform
Oct-16-24	Initiated	Leerink Partners	Outperform
Mar-26-24	Initiated	Guggenheim	Buy
Mar-19-24	Initiated	H.C. Wainwright	Buy
Mar-07-24	Initiated	Citigroup	Buy
Jan-02-24	Upgrade	Wells Fargo	Equal Weight → Overweight
May-10-23	Initiated	Truist	Buy
Mar-10-23	Initiated	Oppenheimer	Outperform
Oct-07-21	Upgrade	Robert W. Baird	Neutral → Outperform
Feb-26-21	Downgrade	Robert W. Baird	Outperform → Neutral
Feb-03-21	Downgrade	BTIG Research	Buy → Neutral
Feb-03-21	Downgrade	Wedbush	Outperform → Neutral
Dec-24-20	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Dec-23-20	Downgrade	Raymond James	Outperform → Mkt Perform
Nov-11-20	Downgrade	Oppenheimer	Outperform → Perform
Nov-10-20	Downgrade	Raymond James	Strong Buy → Outperform
Nov-10-20	Downgrade	Wells Fargo	Overweight → Equal Weight
Mar-19-20	Initiated	The Benchmark Company	Buy
Feb-06-20	Initiated	Oppenheimer	Outperform
Nov-15-18	Upgrade	Raymond James	Outperform → Strong Buy
Sep-10-18	Resumed	BTIG Research	Buy
Sep-10-18	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Jun-04-18	Initiated	H.C. Wainwright	Buy
Mar-12-18	Downgrade	Evercore ISI	Outperform → In-line
Mar-12-18	Downgrade	Wedbush	Outperform → Neutral
Feb-02-18	Initiated	Morgan Stanley	Overweight
Nov-28-17	Resumed	Piper Jaffray	Overweight
Oct-31-17	Initiated	Robert W. Baird	Outperform
Oct-27-17	Initiated	Canaccord Genuity	Buy
Oct-23-17	Reiterated	Stifel	Buy
Oct-12-17	Initiated	Raymond James	Outperform
Aug-17-17	Initiated	Evercore ISI	Outperform
Jul-28-17	Resumed	Stifel	Buy

View All

Voyager Therapeutics Inc Stock (VYGR) Latest News

May 01, 2025

Voyager Therapeutics Announces Appointment of Toby Ferguson as Chief Medical Officer - Stock Titan

May 01, 2025

Apr 30, 2025

BlackRock, Inc. Reduces Stake in Voyager Therapeutics Inc - GuruFocus

Apr 30, 2025

Apr 29, 2025

Voyager Next-Generation CNS Capsids Featured at ASGCT 28th Annua - GuruFocus

Apr 29, 2025

Apr 28, 2025

Voyager Next-Generation CNS Capsids Featured at ASGCT 28th Annual Meeting | VYGR Stock News - GuruFocus

Apr 28, 2025

Voyager Next-Generation CNS Capsids Featured at ASGCT 28th Annual Meeting - GlobeNewswire

Apr 28, 2025

Voyager Therapeutics Presents New Data on Tau Silencing Gene Therapy VY1706 and Anti-Amyloid Gene Therapy at ASGCT Annual Meeting - Nasdaq

Apr 28, 2025

Revolutionary Alzheimer's Gene Therapy Achieves 73% Tau Reduction: Voyager's Breakthrough Data Revealed - Stock Titan

Apr 28, 2025

Apr 27, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 27, 2025

JPMorgan Chase & Co. Decreases Stake in Voyager Therapeutics, Inc. (NASDAQ:VYGR) - Defense World

Apr 27, 2025

Apr 26, 2025

Geode Capital Management LLC Grows Position in Voyager Therapeutics, Inc. (NASDAQ:VYGR) - Defense World

Apr 26, 2025

Apr 21, 2025